Background: 18F-FDG PET/CT has been suggested as an effective tool to stage patients
affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of
hybrid PET/ceCT has emerged.
Objective: To review recent evidence on the role of PET/CT in melanoma staging as well as its potential
for future developments.
Methods: A comprehensive computer literature search of PubMed/MEDLINE was carried out to find
relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.
Results: Some recent studies about potentials and limitations of 18F-FDG PET/CT in staging melanoma,
new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed
Conclusion: PET/CT plays an important role in the staging workup of patients affected by melanoma.
New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in